Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down – Should You Sell?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $10.89, but opened at $9.65. Fulcrum Therapeutics shares last traded at $9.3660, with a volume of 1,679,935 shares traded.

Analyst Ratings Changes

FULC has been the topic of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Thursday, January 22nd. Piper Sandler reissued an “overweight” rating and issued a $23.00 target price (up previously from $16.00) on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Wall Street Zen lowered Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. Truist Financial raised their price target on Fulcrum Therapeutics from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Finally, The Goldman Sachs Group restated a “positive” rating on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.11.

Fulcrum Therapeutics Stock Performance

The stock has a market cap of $490.87 million, a price-to-earnings ratio of -7.68 and a beta of 3.19. The company’s 50 day simple moving average is $10.87 and its 200 day simple moving average is $9.47.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.31). Sell-side analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Insider Buying and Selling at Fulcrum Therapeutics

In other news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of Fulcrum Therapeutics stock in a transaction on Monday, December 8th. The stock was sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the transaction, the insider directly owned 6,053,960 shares in the company, valued at approximately $84,634,360.80. This trade represents a 40.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert J. Gould sold 15,000 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total value of $178,050.00. Following the completion of the sale, the director owned 469,864 shares of the company’s stock, valued at approximately $5,577,285.68. This trade represents a 3.09% decrease in their position. The SEC filing for this sale provides additional information. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Fulcrum Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC purchased a new position in Fulcrum Therapeutics during the 1st quarter valued at about $164,000. Jane Street Group LLC grew its position in Fulcrum Therapeutics by 62.1% during the first quarter. Jane Street Group LLC now owns 117,816 shares of the company’s stock valued at $339,000 after purchasing an additional 45,157 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in Fulcrum Therapeutics by 26.1% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 12,943 shares of the company’s stock valued at $89,000 after buying an additional 2,677 shares during the period. Los Angeles Capital Management LLC acquired a new position in Fulcrum Therapeutics in the 2nd quarter valued at approximately $93,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in Fulcrum Therapeutics by 57.3% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 342,547 shares of the company’s stock worth $2,357,000 after buying an additional 124,798 shares in the last quarter. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.